Media headlines about NovaBay Pharmaceuticals (NYSE:NBY) have trended somewhat positive on Friday, according to Accern Sentiment Analysis. The research group rates the sentiment of media coverage by reviewing more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. NovaBay Pharmaceuticals earned a daily sentiment score of 0.11 on Accern’s scale. Accern also assigned news stories about the company an impact score of 45.7999394315797 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the near term.

Shares of NovaBay Pharmaceuticals (NYSE:NBY) traded up 1.14% during midday trading on Friday, hitting $4.45. 2,133 shares of the stock were exchanged. The firm has a 50 day moving average of $4.33 and a 200 day moving average of $3.69. NovaBay Pharmaceuticals has a 12-month low of $2.25 and a 12-month high of $5.09. The firm’s market cap is $68.13 million.

NovaBay Pharmaceuticals (NYSE:NBY) last posted its quarterly earnings results on Thursday, August 10th. The company reported ($0.11) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.12) by $0.01. The firm had revenue of $4.12 million for the quarter, compared to analysts’ expectations of $4.57 million. NovaBay Pharmaceuticals had a negative net margin of 108.38% and a negative return on equity of 280.84%. Equities analysts forecast that NovaBay Pharmaceuticals will post ($0.46) EPS for the current fiscal year.

NBY has been the topic of a number of analyst reports. Roth Capital set a $6.00 price objective on shares of NovaBay Pharmaceuticals and gave the company a “buy” rating in a report on Sunday, August 20th. Zacks Investment Research upgraded shares of NovaBay Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Wednesday, May 17th. Maxim Group restated a “hold” rating on shares of NovaBay Pharmaceuticals in a report on Friday, August 11th. Finally, HC Wainwright set a $6.00 price objective on shares of NovaBay Pharmaceuticals and gave the company a “buy” rating in a report on Friday, August 11th. Two investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. NovaBay Pharmaceuticals presently has an average rating of “Buy” and a consensus target price of $7.00.

COPYRIGHT VIOLATION NOTICE: “NovaBay Pharmaceuticals (NBY) Getting Somewhat Favorable Press Coverage, Study Shows” was first published by Watch List News and is the property of of Watch List News. If you are accessing this story on another site, it was stolen and reposted in violation of US & international trademark and copyright law. The original version of this story can be read at

About NovaBay Pharmaceuticals

NovaBay Pharmaceuticals, Inc, formerly NovaCal Pharmaceuticals, Inc, is a biopharmaceutical company, which develops products for the eye care market. The Company focuses on commercializing prescription Avenova for managing hygiene of the eyelids and lashes in the United States. Avenova is an eye care product formulated with a form of hypochlorous acid called Neutrox.

Insider Buying and Selling by Quarter for NovaBay Pharmaceuticals (NYSE:NBY)

Receive News & Ratings for NovaBay Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NovaBay Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.